Healthcare Royalty, Inc. (HCRX)
Company Description
Healthcare Royalty is the leading mid-market royalty acquisition company, based upon the number of transactions and aggregate value of capital deployed since 2016.
We focus on growth assets and emerging companies driving innovation in the biopharmaceutical industry. Our mission is to facilitate innovation by deploying capital consistently and reliably in products that serve unmet or underserved medical needs.
We intend to achieve this mission by expanding our portfolio of approved and pre-approval products using cash flow generated by our existing portfolio as well as capital raised in the public equity market and debt raised in the public and private markets.
We have purposefully built a diverse portfolio across the therapeutic spectrum, including blockbuster assets such as Shingrix, innovative growth products such as Krystexxa, and recently launched products such as Xpovio.
Our process for evaluating acquisition and financing opportunities has been optimized through decades of experience and is designed to efficiently assess opportunities, identify risks and establish appropriate Royalty-Related Transaction structures.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 25 |
| CEO | Clarke B. Futch |
Contact Details
Address:
300 Atlantic St, Suite 600 Stamford, CT 06901 United States | |
| Phone | (203) 487-8300 |
| Website | healthcareroyalty.com |
Stock Details
| Ticker Symbol | HCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| CIK Code | 1859651 |
Key Executives
| Name | Position |
|---|---|
| Clarke B. Futch | Chairman and Chief Executive Officer |
| Christopher A. White | President and Chief Financial Officer |
| Timothy R.M. Bryant | General Counsel |
| Thomas K. Conner | Chief Accounting Officer and Treasurer |
| Carlos M. Almodóvar | Chief Business Officer |